Trials / Unknown
UnknownNCT02732535
Natural Killer (NK) Cells Following Bariatric Surgery
The Natural Killer Cells Regulatory Role Against Hepatic Fibrosis Following Bariatric Surgery
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 40 (estimated)
- Sponsor
- Hadassah Medical Organization · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This study will determine the role of the NK cells before and after bariatric surgery. The investigators selected patients with NAFLD. A Fibroscan evaluation will be assessed as a new modality to evaluate liver fibrosis.
Detailed description
All morbidly obese patients who are candidates for a bariatric procedure in the investigators institution who has a fatty liver in their routine preoperative US will undergo a fibroscan to assess the degree of liver fibrosis preoperatively in addition to a blood sample that will be withdrawn from those participants to isolate the NK cells and to assess their activities by the assessment of the active form of NK cells (CD107a) using the spectrometry (FACS) analysis. The investigators will also collect other clinical data including comorbidities (hypertension, diabetes mellitus and hyperlipidemia) in addition to the following routine blood test( complete blood count, creatinine, urea, International normalized ratio, liver function test, HBa1C, cholesterol, HDL, LDL, triglycerides, vitamin D, vitamin B12, potassium, sodium, albumin, bilirubin, C- reactive protein, iron, ferritin and transferrin). All of the above mentioned tests including the NK cells and the fibroscan will be examined for all participants in 3, 6, 12 months postoperatively.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | sleeve gastrectomy , roux-en-y gastric bypass | laparoscopic sleeve gastrectomy or laparoscopic gastric bypass |
Timeline
- Start date
- 2015-08-01
- Primary completion
- 2017-08-01
- Completion
- 2017-12-01
- First posted
- 2016-04-08
- Last updated
- 2016-04-14
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT02732535. Inclusion in this directory is not an endorsement.